VoluMetrix Wins Annual BioPitch Competition at BioFlorida Conference 2020

Share Article

VoluMetrix, a company developing a novel form of vital monitoring (Non-Invasive Venous Waveform Analysis, or NIVA), won the annual “Shark Tank for life sciences” competition, receiving $10,000 in prize funding. VoluMetrix is developing NIVA for a wide range of healthcare applications, including volume status monitoring for heart failure.

VoluMetrix, a Nashville-based company dedicated to creating a new wave of solutions for vital monitoring to enhance well-being, today announced that it has won BioFlorida’s 2020 BioPitch competition. BioPitch takes place at the BioFlorida Annual Conference and is an annual competition for seed and early stage life science companies.

VoluMetrix is developing a novel form of vital monitoring, Non-Invasive Venous Waveform Analysis (NIVA), for a wide range of healthcare applications, with potential near-term clinical applications that include vital monitoring for heart failure and pulmonary disease.

As part of the competition, 12 semi-finalists pitched to a closed-door panel of judges. Three finalists were then selected to present a live pitch at BioPitch, held on October 28. VoluMetrix was announced the winner, receiving $10,000 in prize capital.

“Our BioPitch competition provides the opportunity for some of the most innovative companies currently seeking seed and early-stage investment to pitch to life science investors,” said Nancy K. Bryan, President & CEO of BioFlorida. “We’re excited about the unique VoluMetrix technology with its potential to enhance our ability to monitor heart failure patients’ volume status.”

Non-Invasive Venous Waveform Analysis (NIVA) technology represents a major paradigm shift from existing vital monitoring technology. NIVA optimizes hemodynamic assessment in three key ways: signal capture (using a non-invasive wrist sensor), signal deconstruction (mapping individual amplitudes within a patient’s waveform), and signal decoding (via a proprietary NIVA Score that corresponds to industry-standard pulmonary capillary wedge pressure, PCWP).

“Given the caliber of our fellow nominees, we’re honored to be chosen as this year’s BioPitch winner,” said Kyle Hocking, Ph.D., President & CEO, VoluMetrix. “We believe that our technology has the potential to empower healthcare providers and their patients in many care areas, and we look forward to announcing additional milestones as we develop NIVA for targeted clinical applications.”

The first anticipated clinical application of NIVA will be NIVAʜғ for venous waveform monitoring in heart failure patients. NIVAʜғ is currently in Verification and Validation, with submission to the FDA for clearance via the de novo pathway expected in Q1 2021. NIVA is also being investigated for venous waveform monitoring pulmonary function in patients suffering from pulmonary disease (including COVID-19). Future potential applications include pediatric care, kidney failure, trauma, sepsis, and mental and consumer health.

To date, NIVA technology has been studied for multiple potential clinical applications, including for hemodynamic-guided heart failure management; noninvasive assessment of congestion in spontaneously breathing patients; detection of early blood loss that may be useful in early triage and perioperative management; volume directed dialysis to prevent intradialytic hypotension; and measuring intravascular volume changes for children undergoing surgery.

What is the Venous Waveform?
The venous waveform is an energy-based signal generated by heart and respiratory activity that reflects numerous physiologic conditions, including pulse and respiratory rate, as well as intravascular and extravascular dynamics.

About VoluMetrix
VoluMetrix is a Nashville-based company, closely aligned with Vanderbilt University in Nashville, TN and a member of the Mayo Clinic Innovation Exchange in Jacksonville, FL, that is dedicated to creating a new wave of solutions for vital monitoring to enhance well-being. As pioneers of non-invasive venous waveform technology, we are partnering closely with patients and practitioners to develop the pathway towards the optimal implementation and utilization of our technology, from hospital to home.

The NIVA technology is investigational and is not available for sale in the United States.

For more information, please visit our website at https://www.volumetrix.com/ or Linkedin at https://linkedin.com/company/volumetrix.

About BioFlorida
BioFlorida is the voice of Florida’s life science industry, representing 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors that collectively employ 94,000 Floridians. BioFlorida’s member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state. Learn more by visiting http://www.bioflorida.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Annie Alvis
+1 (615) 219-9536
Email >
Visit website